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Abstract
Background: Increasing the breadth of the functional antibody response through immunization with Plasmodium
falciparum apical membrane antigen 1 (PfAMA1) multi-allele vaccine formulations has been demonstrated in
several rodent and rabbit studies. This study assesses the safety and immunogenicity of three PfAMA1 Diversity-
Covering (DiCo) vaccine candidates formulated as an equimolar mixture (DiCo mix) in CoVaccine HT™ or
Montanide ISA 51, as well as that of a PfAMA1-MSP119 fusion protein formulated in Montanide ISA 51.
Methods: Vaccine safety in rhesus macaques was monitored by animal behaviour observation and assessment of
organ and systemic functions through clinical chemistry and haematology measurements. The immunogenicity of
vaccine formulations was assessed by enzyme-linked immunosorbent assays and in vitro parasite growth inhibition
assays with three culture-adapted P. falciparum strains.
Results: These data show that both adjuvants were well tolerated with only transient changes in a few of the
chemical and haematological parameters measured. DiCo mix formulated in CoVaccine HT™ proved
immunologically and functionally superior to the same candidate formulated in Montanide ISA 51. Immunological
data from the fusion protein candidate was however difficult to interpret as four out of six immunized animals
were non-responsive for unknown reasons.
Conclusions: The study highlights the safety and immunological benefits of DiCo mix as a potential human
vaccine against blood stage malaria, especially when formulated in CoVaccine HT™, and adds to the accumulating
data on the specificity broadening effects of DiCo mix.
Background
The development of an effective malaria vaccine remains
an important public health objective for disease control
in endemic areas. Vaccine strategies that control or pre-
vent blood stage infection may be most desirable since
blood stage parasites are responsible for clinical symp-
toms of the disease. Current knowledge of Plasmodium
falciparum, the parasite responsible for the most severe
form of disease suggests that a potentially effective vac-
cine would likely include multiple antigens, preferably
expressed in different stages of the parasite’s life cycle.
Essential P. falciparum antigens that are currently being
considered as subunit vaccine candidates include apical
membrane antigen 1 (AMA1) and merozoite surface pro-
tein 1 (MSP1). AMA1 is highly polymorphic and is found
in both merozoite and sporozoite stages of the parasite
[1-4]. It is initially expressed as an 83 kDa precursor pro-
tein in the micronemes and undergoes an N-terminal
prosequence cleavage to form the 66 kDa antigen at the
same site [5]. AMA1 translocates to the parasite mem-
brane surface at the time of red cell invasion, and plays a
k e yr o l ei nt h ei n v a s i o np r o c e s s[ 5 - 9 ] .T h eA M A 1e c t o -
domain, which is the vaccine target, is shed as 44 and
48 kDa alternate antigens before the parasite enters the
red cell [5,10]. The ectodomain has 16 cysteine residues
that form disulphide bonds to divide the antigen’s tertiary
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[11].
MSP1, another important vaccine candidate, is the para-
site major surface antigen that also plays a role in the red
cell invasion process and is dimorphic [12-15]. MSP1 is
expressed as a precursor protein of approximately
200 kDa on the surface of developing merozoites [16]. It is
proteolytically processed into several fragments at the time
of schizont rupture and red cell invasion. The 42 kDa frag-
ment, which is a vaccine candidate, is subsequently pro-
cessed into 33 kDa and 19 kDa fragments [17,18]. The
19 kDa fragment (MSP119), which is a major vaccine tar-
get, remains anchored to the merozoite surface and can be
detected in early red cell stages of the parasite [19,20]. All
other MSP1 fragments are shed as a peptide complex
prior to red cell invasion.
These antigens have demonstrable vaccine properties in
rodent and non-human primate models as well as in in
vitro systems [21-27]. Their vaccine potential, which is
exhibited mainly through antibody-mediated mechanisms
[28,29], is however limited by allelic polymorphism
[24,26,30-32]. Multi-allele vaccination studies, mostly in
rabbits and rodents, have however shown promise in over-
coming the strain-specific effects of polymorphism on
immune responses to these antigens. This strategy
informed the design, expression and purification of three
Diversity-Covering (DiCo) P. falciparum AMA1 (PfAMA1)
antigens based on the sequences of 355 naturally occurring
PfAMA1 alleles [33]. The DiCo vaccine candidate is an
equimolar mixture (DiCo mix) of the three DiCo antigens,
h e n c ea p a r tf r o mt h ed e s i g ns t r a t e g yw h i c hi st oc o v e r
polymorphism, mixing of the three DiCo antigens cover
polymorphism on a second level. DiCo mix formulated
with either Montanide ISA 51 or CoVaccine HT™ as adju-
vant has been shown to induce rabbit humoral responses
with similar high inhibitory capacities against multiple
parasite strains in vitro [33,34]. Another strategy for dam-
pening the effects of polymorphism on PfAMA1 responses
is to combine PfAMA1 candidates with other highly
immunogenic candidates that show limited polymorphism.
This second strategy may involve mixing of the separately
expressed and purified vaccine component antigens, or the
expression and purification of component antigens as a
single chimeric protein. In one such study, rabbits were
immunized with PfMSP119 (Welcome strain) and PfAMA1
(domains I and II of the FVO strain) proteins formulated
as a mixture or the expressed chimeric proteins in Monta-
nide ISA720 and functionality of induced IgGs was tested
against three parasite strains (FCR3, HB3, 3D7). IgG
responses to PfAMA1 alone or the PfAMA1/PfMSP119
vaccine products showed signs of strain specificity in func-
tional assays, while responses to products containing
PfMSP119 alone showed limited strain-specificity [35].
Challenge studies in rodents immunized with a cocktail of
Plasmodium chabaudi AMA1 and MSP142 antigens also
showed a greater reduction in peak parasitaemia compared
to separate immunizations with the single antigens [36].
Another study involving a combination vaccine that con-
sists of PfAMA1 and PfMSP142 yielded responses that were
directed against both antigens, though protection induced
by the combination vaccine was not superior to that
induced by the PfAMA1 vaccine alone [27].
Most pre-clinical evaluations of these immunization
strategies are done in rodents and rabbits. Vaccine evalua-
t i o ni nam o n k e ym o d e l ,t h o u g hn o tl e g a l l ym a n d a t o r y ,
may be an important step as it could yield additional data
on vaccine safety and immunogenicity [37]. The in vitro
parasite growth inhibition assay may have some limitations
when used for assessment and down-selection of poten-
tially important candidates, whose vaccine effects might be
mediated by any of a number of different mechanisms. It
nevertheless gives some idea of in vivo functionality, espe-
cially for antibody responses that are known to have a
direct blocking effect on antigen processing and/or host
cell invasion. In the current study the capacity of the DiCo
mix and PfAMA1-MSP119 candidates, formulated in either
Montanide ISA 51 or CoVaccine HT™ as adjuvants, to
induce functional broad-strain antibody responses in non-
human primates was examined. The safety and tolerability
of these adjuvant formulations were also assessed as a
proxy to effects that are likely to be observed in clinical
testing of these candidates.
Methods
Antigens
All antigens were expressed as recombinant proteins in
Pichia pastoris systems and details of gene expression and
protein production have already been described elsewhere
[33,35,38]. Natural PfAMA1 alleles comprise the full
length ectodomain (25-545) of the CAMP [GenBank:
M58545], 3D7 [GenBank:U65407), HB3 [GenBank:
U33277] and FVO [GenBank:AJ277646] strains of P. falci-
parum.D i C op r o t e i n sc o n s i s to fa m i n oa c i d s9 7-5 4 5o f
the AMA1 ectodomain (domains I, II and III, without the
signal sequence). The PfAMA1-MSP119 fusion protein
(designated AM) consists of amino acids 106 - 442
(domains I and II) of the FVO AMA1 ectodomain fused
w i t ham u t a n tf o r mo fPfMSP119 (amino acids 1526 -
1621) of the Wellcome strain of P. falciparum [35]. All
antigens were recognized by the reduction-sensitive rat
monoclonal 4G2 antibody suggesting a correct folding of
proteins. All antigens were devoid of N-glycosylation sites
and the molecular size of the fusion protein product is
comparable to that of any of the AMA1 proteins.
Animal welfare and ethical clearance
Animals used in this study were captive-bred for
research purposes. Experimentation and housing were at
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facility in Rijswijk, the Netherlands, in accordance with
Dutch laws and European Acts (directive 86/609/EEC)
on animal experimentation. The BPRC is compliant
with recommendations of the Weatherall report on the
use of non-human primates in research [39]. The study
was approved by an independent ethics committee at
BPRC, constituted in accordance with Dutch law on ani-
mal experimentation. To minimize discomfort to ani-
mals, immunization and blood sampling were all done
under ketamine sedation. The study involved three
experimental groups, each with six rhesus monkeys.
Animals were assigned in a manner that ensured that
age, weight and sex were similar amongst groups, and
treatments were randomly assigned to groups.
Vaccine formulation, immunization and bleeding
Two of the three groups of rhesus macaques were immu-
nized with DiCo mix in either Montanide ISA 51 (Seppic,
Paris, France) or CoVaccine HT™ (Protherics Medicines
Development Limited, A BTG International Group Com-
pany, London, UK) as adjuvant, and the third group was
immunized with the AM fusion protein formulated in
Montanide ISA 51. Formulations were made under sterile
conditions according to the respective adjuvant manufac-
turers’ protocols. For Montanide ISA 51 formulations,
276 μl of antigen solution (130 μg/ml of DiCo mix or
217 μg/ml of AM) was added to 324 μlo fa d j u v a n ta n d
the mixture emulsified by 20 passages through a Teflon-
coated 22 gauge syringe-coupling piece. Five hundred
microlitres (500 μl) of this formulation was administered
per animal. For CoVaccine HT™ formulation, 300 μlo f
DiCo mix (120 μg/ml in saline) was mixed with an equal
volume of adjuvant to a sucrose fatty acid sulphate esters
(SFASEs) concentration of 20 mg/ml. Five hundred micro-
litres (500 μl) of the resulting mixture with 10 mg SFASEs
was administered after gentle mixing. Animals were
immunized intramuscularly in alternating legs on days 0
(left), 28 (right) and 56 (left) with either 30 μgo fD i C o
mix (two groups, designated DiCo/ISA and DiCo/HT) or
50 μg AM fusion protein (1 group, designated AM/ISA).
Small aliquots of blood (between 2 ml and 7 ml) were
taken on days 0, 1, 7, 14, 28, 29, 35, 42, 56, 57, 63 and 70
for clinical chemistry, serology and haematology, and
larger volumes (up to 27 ml) were taken on Day 70 for
serology, IgG isolation and subsequent in vitro testing.
Safety monitoring
All treatment groups were monitored for safety by the
assessment of local reactions (Draize scores), behaviour,
appetite, stool and bodyweight as well as by clinical chem-
istry and haematology. Injection sites were inspected for
local reactions on days 0, 1, 7 and 14 after each vaccina-
tion. Animals were also monitored on a daily basis by the
caretakers and injection sites were frequently inspected.
Clinical chemistry to assess organ and systemic functions
was performed with a Cobas Integra 400 analyzer (Roche
Diagnostics, Basel, Switzerland) according to standard
methods and compared with normal values based on
cumulative data from healthy animals within the same ani-
mal facility. Parameters measured include alkaline phos-
phatase, alanine transaminase, aspartate transaminase,
bilirubin, lactate dehydrogenase, gamma glutamyl trans-
peptidase, cholesterol, glucose, iron, potassium, sodium,
calcium, phosphate, chloride, bicarbonate, albumin, creati-
nine, total protein and urea. Haematology was performed
with an automated analyser (Sysmex XT 2000iV platform;
Goffin Meyvis, Etten-Leur, the Netherlands) and measure-
ments were made for the red blood cell fraction (haemo-
globin levels, erythrocyte count, haematocrit, mean
corpuscular volume, mean corpuscular haemoglobin) and
for the white blood cell fraction (white blood cell, lympho-
cyte, neutrophil, monocyte, eosinophil and basophil
counts) as well as for platelets and mean platelet volume.
Safety assessments were made before immunization
and one day, one week and two weeks following each
immunization. Since all parameters had returned to nor-
m a lv a l u e sb yd a y7 0 ,b o d yw e i g h tw a st h eo n l yp a r a -
meter monitored on days 99 and 126.
Immunological assessment of vaccine responses
Anti-AMA1 IgG levels in serum samples from blood
drawn before immunization on days 0, 28 and 56, as well
as samples taken on days 14, 42, 70, 99 and 126 were
determined using an indirect ELISA. IgGs were measured
against seven different PfAMA1 alleles (the three DiCo
antigens and recombinant PfAMA1 alleles from the FVO,
HB3, 3D7 and CAMP parasite strains). Anti-MSP119 IgG
levels in the AM vaccine group were measured with
MSP119 as capture antigen. Briefly, plates were coated
with 0.5 μg/ml of the relevant antigen in PBS and subse-
quently blocked with 3% BSA in PBS with 0.05% Tween
20. Serum samples were diluted in PBS containing 0.1%
BSA and 0.05% Tween-20. A pool of hyperimmune sera
with high AMA1 and MSP119-specific antibody titres was
included on each plate as a standard calibrator. Antibodies
were detected with an affinity-purified anti-human IgG
coupled to alkaline phosphatase. Plates were developed
with 1 mg/ml para-nitrophenyl phosphate, and the absor-
bance at 405 nm was measured. Antibody titres were sub-
sequently expressed in arbitrary units (AU), with 1AU
being equivalent to the reciprocal dilution at which an
absorbance of 1 over background is achieved.
Antibody functionality was assessed by in vitro growth
inhibition assays using the FCR3 (with one prodomain
amino acid difference from AMA1 of the FVO strain
[GenBank:M34553]), NF54 (parent clone of the 3D7
clone, [GenBank:U65407]) and HB3 [GenBank:U33277]
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described [33,38]. Antibodies were purified from day 70
sera using Protein A Sepharose (GE Healthcare, Etten-
Leur, The Netherlands) columns and used at a final
concentration of 10 mg/ml. Parasite strains were verified
by restriction fragment length analysis and cultures were
shown to be negative for mycoplasma.
Data analyses
Clinical chemistry and haematological data assessment
was based on normal reference values calculated from
cumulative data of similar measurements in healthy ani-
mals within the same facility. IgG titres determined by
ELISA for the different immunization groups were log-
transformed to achieve normality and compared by one-
way analysis of variance (ANOVA). Tukey HSD post hoc
test with correction for multiple comparisons was used for
pair-wise comparison of IgG titres in the same immuniza-
tion groups against different capture antigens. Student t
tests were used for the pair-wise comparison of GIA data
between immunization groups against the same parasite
strain, while the Tukey HSD post hoc test was used to
compare data for the same immunization group against
different strains. ELISA antibody titres and GIA data from
day 70 sera (or purified IgG) are also presented as dotplots
superimposed with boxplots showing the median inhibi-
tion as well as the first and third quartiles per treatment
group. Plot symbols represent individual animals within
the same treatment group. All graphics and analyses were
performed using the R statistical package (R Development
Core Team, 2010, version 2.12.1).
Results
Safety monitoring
Vaccine formulations with both adjuvants were generally
well tolerated. All animals maintained body weights within
reference ranges of normal values for the entire duration
of the study. There were also no major changes in beha-
viour, appetite or stool over the period of observation.
Apart from palpable inguinal lymph nodes there were no
notable local reactions (oedema, erythema, indurations) in
all 18 study animals. Levels of aspartate transaminase in
the DiCo/ISA immunization group as well as alanine
transaminase and bilirubin in the AM/ISA group showed
slight increases on the days following immunization but
returned to normal levels within a week. There was an
increase in creatinine levels a day after immunization in
the DiCo/HT group but these also returned to normal
levels within a week. Creatinine levels in the DiCo/ISA
group were however above normal values at the start of
the study and remained at similar high levels throughout
the observation period. Levels of blood iron decreased on
the days following immunization in the DiCo/HT group
but also returned to normal levels within a week. All other
measured clinical chemistry parameters were within nor-
mal reference ranges throughout the 70-day observation
period.
Of the parameters measured for haematology, increases
in neutrophil count (and hence white blood cell count)
were observed a day after each immunization, but these
again returned to normal values within a week. All other
measured parameters were between normal ranges
throughout the study.
Generally, local reactions were limited to mild reddening
of the injection site area, and these resolved within a few
days. One animal in the AM/ISA group however devel-
oped stiffness in the upper leg muscle to a degree that lim-
ited movement of the left leg. This adverse event was first
observed 14 days after the last immunization (day 70) and
had not resolved on day 126. Given this observation,
which lasted for more than 56 days, the amount of dis-
comfort to this animal was rated moderate to serious.
Elisa antibody responses
IgG levels against seven AMA1 alleles and MSP119 at all
sampling time points were determined using a harmonized
ELISA. The three vaccine formulations induced appreci-
able levels of antibodies against the tested antigens and
titres against all antigens increased in a similar manner
and generally peaked on day 70, two weeks after the final
vaccine injections were given. IgG titres against the FVO
AMA1 allele at all time-points are presented in Figure 1
and day 70 titres against all antigens are presented in
F i g u r e2 .B e y o n dd a y7 0 ,I g Gt i t r e si nt h et w oD i C om i x
immunization groups showed a decline that was statisti-
cally significantly lower on day 126 compared to day 70
levels (p < 0.05 for all AMA1 antigens, Student t test).
Both the anti-AMA1 and anti-MSP119 levels for the AM/
ISA group were however not significantly different on
days 70 and 126 (p > 0.05, Student t test).
Vaccine-induced IgG titres against all seven AMA1
capture antigens were generally highest in the DiCo/HT
group by day 70. A comparison of the geometric mean
titres, either for the same immunization group against
all AMA1 antigens, or for all groups against the same
capture antigen, showed that there were no statistically
significant differences (P > 0.05, one-way ANOVA).
Anti-AMA1 IgG titres varied most amongst animals in
the AM group, with four of the six animals having very
low IgG titres against all antigens and the other two
having exceptionally high titres (Figure 2).
Anti-MSP119 IgG titres were determined only for the
AM group (Figure 2), and these were statistically com-
parable to anti-AMA1 IgG titres against all seven
AMA1 capture antigens for the same group (p = 0.99,
o n e - w a yA N O V A ) .T h ef o u ra n i m a l sw i t hl o wa n t i -
AMA1 IgG levels in this group also had the lowest anti-
MSP119 IgG levels.
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In vitro growth inhibition assays were performed on
the FCR3, HB3 and NF54 culture-adapted strains of P. fal-
ciparum using protein G-purified IgGs from day 70 sera.
Purified IgGs were tested against each parasite strain at a
final concentration of 10 mg/ml, and the data, presented in
Figure 3, is the average of two independent assays per para-
site strain. The amino acid sequence differences between
the three DiCo antigens and the AMA1 alleles expressed
by the P. falciparum strains used in assays is presented in
Figure 4. All animals in the DiCo/HT group responded
well to the vaccine by eliciting levels of IgG that substan-
tially inhibited parasites, while IgGs elicited by one animal
in the DiCo/ISA group and four animals in the AM/ISA
group had growth inhibition levels lower than 20% against
all three strains. Growth inhibition levels for the AM/ISA
group therefore had a very wide range.
At 10 mg/ml, IgGs from the DiCo/HT group had mean
growth inhibition (56.3%, 57.8% and 83.7% for FVO, HB3
and NF54 strains, respectively) that was significantly
higher than that of IgGs from the DiCo/ISA group (31.0%,
33.2% and 56.8% for FVO, HB3 and NF54 strains,
Figure 1 Anti-FVO AMA1 IgG titres in sera of animals immunized with AMA1-based vaccines. Three groups of six rhesus monkeys each
were immunized with PfAMA1-based formulations on days 0, 28 and 56. One group was immunized with DiCo mix formulated in CoVaccine
HT™ (DiCo/HT), the second group with DiCo mix in Montanide ISA 51 (DiCo/ISA), and the third group with an AMA1-MSP119 fusion protein in
Montanide ISA 51 (AM/ISA). IgG titres in samples taken prior to each immunization, as well as in samples drawn on days 14, 42, 70, 99 and 126,
were measured by an indirect ELISA. Similar patterns were observed for IgG measurements against six other PfAMA1 alleles (vaccine antigens
DiCo 1, DiCo 2 and DiCo 3 as well as PfAMA1 from the HB3, 3D7 and CAMP parasite strains). For each panel, the different colours/symbols
represent individual animals.
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FCR3 strain, p = 0. 033 for HB3 and p = 0.006 for NF54,
student t test). Mean growth inhibition was significantly
higher for the DiCo/HT group compared to the AM/ISA
group (32.5%) against the NF54 strain alone (p = 0.026),
while differences between the DiCo/ISA and AM/ISA
groups against all three strains were not statistically signifi-
cant (p > 0.05 in all cases). It must be noted that IgGs
from one animal in the DiCo/HT group completely inhib-
ited the NF54 strain, with the average of the two measure-
ments being above 100%, an obvious artefact.
Comparison of mean growth inhibition per immuniza-
tion group amongst the three parasite strains showed
that IgGs from the DICo/HT group inhibited NF54
parasites better than the other two strains (p = 0.003
against FCR3 and p = 0.005 against HB3, Tukey HSD).
Mean inhibition for this group however did not differ
between HB3 and FCR3 parasites (p = 0.973, Tukey
HSD). Mean inhibition against the three parasite strains
was similar for both the DiCo/ISA and AM/ISA groups
(p = 0.85 for AM/ISA and p = 0.076 for DiCo/ISA, one-
way ANOVA). In this study, inhibition of the growth of
the NF54 parasite strain was unexpectedly high in com-
parison with the other two strains.
Discussion
Multi-allele and multi-antigen malaria vaccine
approaches have shown potential in inducing antibody
Figure 2 IgG titres in day 70 sera from all three immunization groups.A n t i - PfAMA1 titres in all immunization groups were measured
against seven allelic vaccine antigens (DiCo 1, DiCo 2 and DiCo 3 as well as PfAMA1 from the FVO, HB3, 3D7 and CAMP parasite strains) while
anti- MSP119 IgG levels in the AM/ISA group were measured against PfMSP119. For each immunization group, plot symbols represent data from
individual animals in all panels. Plot symbols are also the same as those used for the same animals in Figure 1.
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number of rodent and rabbit studies [33,34,40]. In the
current study, the immunological benefits of such
immunization strategies, asw e l la st h es a f e t yo ft h e s e
formulations, were further analysed in a non-human pri-
mate model. Two different adjuvants were used for vac-
cine formulation in this study; Montanide ISA 51 (w/o)
is a proprietary adjuvant from Seppic (Paris, France) and
has been used in a number of human studies [41-43].
CoVaccine HT™ (o/w) is also a proprietary adjuvant
developed by Protherics Medicines Development Lim-
ited, a BTG International Group company, and has
recently entered human trials [44]. In the current study
both adjuvant formulations were well tolerated as most
of the parameters (chemistry and haematology) mea-
sured to assess organ and systemic functions were well
within normal values for healthy animals within the
same facility. Palpable inguinal lymph nodes were the
only local reaction to vaccination observed in study ani-
mals. Mean levels of alanine transaminase in the AM/
ISA immunization group and aspartate transaminase in
the DiCo/ISA group increased a day after each immuni-
zation but were back to baseline within a week. Transi-
ent increases were seen in individual animals in all
immunization groups but only those in groups immu-
nized with Montanide ISA 51 showed mean levels
higher beyond normal values. Hypotension and hypox-
aemia induced following ketamine sedation have been
Figure 3 In vitro parasite growth inhibition levels of protein A-purified IgGs from day 70 samples. IgGs were tested in triplicate at a final
concentration of 10 mg/ml against the FCR3, HB3 and NF54 culture-adapted strains of P. falciparum. The data presented is the average of two
independent assays, and plot symbols represent data from individual animals within the same immunization group in all panels. Plot symbols
are also the same as that used for the same animals in other figures.
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and heart muscle [45,46] and it is possible that Monta-
nide ISA 51 enhanced this effect.
Mean levels of creatinine for the DiCo/ISA group were
high throughout the study period, with four of the six
animals in the group showing levels above normal prior
to the first immunization and throughout the study. As
these levels remained largely unchanged throughout the
study, it suggests that treatments did not alter renal func-
tion. Increased neutrophil counts in the DiCo/HT group
following immunization were concomitant with
decreased levels of serum iron in the same group. This
observation has also been made in previous studies and is
suggestive of the possibility that these events are coupled.
The limited leg movement experienced by one animal in
the AM/ISA group was most likely due to physical injury
from needles used to deliver the vaccine or for blood
sampling and not vaccine-related. Moreover, such an
outcome has not been observed in earlier studies in this
lab with this adjuvant.
Previous studies with CoVaccine HT™ formulations at
a nS F A S E sd o s eo f2m go r1 0m gi nr h e s u sm o n k e y s
[47,48] and at 2 mg or 4 mg SFASEs in rabbits [47]
showed no local or systemic adverse events, while only
minimal transient adverse events were seen in a small per-
centage of ferrets with formulations containing 0.125 -
4 mg of SFASEs ([47,49]). For Montanide ISA 51, though
little to no reactogenicity has been reported in animal stu-
dies and in some human studies [41,50-52], other human
studies have concluded that this adjuvant, with its current
composition, might not be suitable for use in humans due
to high reactogenicity [42,43].
Mean antibody responses against the AM/ISA vaccine
were statistically similar on day 70 and 126 while
responses against the two DiCo mix groups had declined
significantly by day 126. This was due mainly to the excep-
tionally high titres in two of the six animals in the AM/
ISA group (Figure 1) and does not reflect a more durable
IgG response against the AM fusion protein compared to
DiCo mix, especially since the four low responders in the
AM group also showed titre decreases on day 126. The
AM/ISA vaccine also induced appreciable levels of anti-
MSP119 IgG, especially in the two animals that also had
the highest anti-AMA1 IgGs in this group. Vaccine design
studies with MSP119 fusion proteins have shown that IgG
responses induced against the MSP119 component
increase several fold compared to IgG responses to formu-
lations with MSP119 alone [35,53], suggesting that fusion
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DiCo 1 YVYLSKNVVDNWEKVCPRKNLENAKFGLWVDGNCEDIPHVNEFSAIDLFECNKLVFELSASDQPKQYEQHLTDYEKIKEGFKNKNADMIRSAFLPTGAFKADRYKSHGKGYNWGNYNRKTQKCEIFNVKPT
DiCo 2 ---------------------------------------------N-------------------------------------------------------------------------------------
DiCo 3 ---------H---E-------Q-----------------------N------------------------------------------------------------R----------TE------------
FCR3 -T-----------E-------------------------------N----------------------------------------S--K----------------------------E------------
HB3 -T-----------E-------------------------------N----------------------------------------S--K----------------R----------TE------------
NF54 -T-------------------Q---------------------P------------------------------------------S--K---------------------------TE------------
--420--*----430--*----440--*----450--*----460--*----470--*----480--*----490--*----500--*----510--*----520--*----530--*----540--*
DiCo 1 CLINDKSYIATTALSHPIEVEHNFPCSLYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKCPCDPEIVSQSTCNFFVCKCVEKRAEVTSNNEVVVKEEYKDEYADIPEHKPTYDKM
DiCo 2 ------------------------------N--M----------------------------------------------------------------------------------------------
DiCo 3 -----------------N---N---------------------------------------------I-------A--M------R--------R-------------------------------N-
FCR3 ----NS------------------------------------------------------------------------M--N---R--------R-------------------------------N-
HB3 ----NS-----------N---N-----------------------------------------------------------N--------------------------------------------N-
NF54 ----NS---------------N-----------M--------------------------------------------M--N---R--------R---------------------------------
Figure 4 Protein sequence (aa 25 - 545) alignments for DiCo antigens and parasite AMA1 alleles. AMA1 protein sequences of malaria
parasites used for in vitro growth inhibition assays were accessed from the GenBank database. The DiCo sequences contain point mutations at
the cleavage (K376R, indicated in orange) and potential N-glycosylation (N162Q, T288V, S373D, N422D, S423K, N499Q, indicated in red) sites and
differ from parasite AMA1 sequences at these sites. Amino acid residues 25 to 96 represent the prodomain of the AMA1 transmembrane protein,
residues 97 - 303 represent domain I, residues 304 - 440 represent domain II and residues 441 - 545 represent domain III of the protein
ectodomain.
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Page 8 of 11enhances antibody formation against the MSP119
component.
Observations in ELISA were in agreement with the in
vitro growth inhibition data as animals with high IgG
levels had correspondingly high GIA activities and vice
versa. Purified IgGs from all animals in the DiCo/HT
group showed high mean growth inhibition of the three
parasite strains compared to inhibition by IgGs in ani-
mals from the DiCo/ISA group (Figure 3). This suggests
that the CoVaccine HT™ formulation was functionally
superior and that this adjuvant may be most suitable for
inducing the required high titres of functional IgGs.
Inhibition of all three strains was similar for all IgGs
from the DiCo/ISA or AM/ISA immunization groups
(Figure 3). Inhibition of NF54 parasites by IgGs from
the DiCo/HT group was however slightly higher com-
pared to that of the two other strains (Figure 3). This
can however not be attributed to greater sequence simi-
larity between NF54 AMA1 and the DiCo antigens.
Indeed the greatest sequence similarity for the AMA1
allele sequences indicated in Figure 4 is between the
FVO AMA1 allele and DiCo 2 (12 amino acid differ-
ences apart from the one cleavage and six N-glycosyla-
tion site differences). This notwithstanding, the data
demonstrate the specificity broadening benefits of DiCo
mix formulations in non-human primates, and adds to
the accumulating data on the strain-transcending prop-
erties of the DiCo strategy that have been demonstrated
in rabbit studies [33,34].
Four animals in the AM/ISA group had very low IgG
titres (Figure 2) with corresponding low inhibitory activ-
ities below 20%, especially against the HB3 and NF54
strains (Figure 3). The other two animals in this group had
high vaccine responses in both ELISA and GIA (Figures 1
and 2) hence the weak responses in the four animals can-
not be due to poor immunogenicity of the candidate anti-
gens. Thus these animals were most likely non-responsive
to immunization, and this makes it difficult to draw firm
conclusions on the effectiveness of the AM fusion protein
candidate in this study. Parasite inhibition studies done in
vitro with antibodies raised in rabbits as well as challenge
studies in mice have however shown that vaccines com-
posed of AMA1 and MSP1 either as a mixture or a fusion
protein product induced functional antibodies [35,36,54].
The data presented shows that both adjuvant formula-
tions were well tolerated upon administration to rhesus
macaques. The data further demonstrates the specificity
broadening benefits of multi-allele formulations compared
to single PfAMA1 formulation in non-human primates
[55,56], and adds to the accumulating data on the strain-
transcending properties of the DiCo strategy. The three
antigens, especially when formulated in CoVaccine HT™,
induced IgG levels that inhibited multiple parasite strains
in vitro. It is however difficult to draw firm conclusions on
data from the AM fusion protein since most of the test
animals immunized with this vaccine showed low vaccine
responses. The DiCo antigens thus represent a unique
strain-transcending strategy for developing a malaria
blood stage vaccine with benefits for susceptible indivi-
duals in areas where P. falciparum is endemic.
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